
Opinion|Videos|April 10, 2025
Operationalizing TAR-200 and Other Delivery Systems in Practice
Experts discuss whether novel delivery systems in non–muscle-invasive bladder cancer (NMIBC) could be easily adopted in clinical practice and the challenges they anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Looking forward, do you believe novel delivery systems in NMIBC could be easily adopted in clinical practices?
- What challenges do you anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5









